SBS-IF is the second orphan disease target indication for Jaguar’s intestinal failure program, which includes microvillus inclusion disease (MVID) – for which the company completed a meeting in ...
PRESS RELEASEAB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A ...
The firm will share updated data and new analyses from its Phase III trial with the agency, which issued a complete response ...
Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome. Read why KYTX ...
We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...
InvestorsHub on MSN
FibroGen shares advance after roxadustat earns orphan drug status
Shares of FibroGen, Inc. (NASDAQ:FGEN) climbed about 3% on Monday after the company said its drug candidate roxadustat has ...
Company is on track to file the Phase 3 protocol in the fourth quarter of 2025SAN FRANCISCO, (GLOBE NEWSWIRE) -- FibroGen, Inc.
Officially lowering the evidentiary bar creates a predictable risk: more companies may highlight their most favorable study while downplaying or withholding less supportive results -- data the public ...
Only 6% of trials for FDA-approved drugs match America's diversity. Analysis reveals how trial location and design choices ...
The patchwork rollout of a gene therapy exposes weaknesses in the pricing and regulatory frameworks that determine who ...
We recently published 13 Best ADR Stocks to Invest In . GSK plc (NYSE:GSK) is one of the best ADR stocks.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback